MX2022010171A - Inhibidores de setd2 y metodos y usos relacionados. que incluyen terapias de combinación. - Google Patents

Inhibidores de setd2 y metodos y usos relacionados. que incluyen terapias de combinación.

Info

Publication number
MX2022010171A
MX2022010171A MX2022010171A MX2022010171A MX2022010171A MX 2022010171 A MX2022010171 A MX 2022010171A MX 2022010171 A MX2022010171 A MX 2022010171A MX 2022010171 A MX2022010171 A MX 2022010171A MX 2022010171 A MX2022010171 A MX 2022010171A
Authority
MX
Mexico
Prior art keywords
inhibitors
related methods
combination therapies
setd2
include combination
Prior art date
Application number
MX2022010171A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Anne Totman
Maria Alejandra Raimondi
John Lampe
Katherine Louise Cosmopoulos
Vinny Motwani
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2022010171A publication Critical patent/MX2022010171A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022010171A 2020-02-19 2021-02-19 Inhibidores de setd2 y metodos y usos relacionados. que incluyen terapias de combinación. MX2022010171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978692P 2020-02-19 2020-02-19
PCT/US2021/018863 WO2021168313A1 (en) 2020-02-19 2021-02-19 Setd2 inhibitors and related methods and uses, including combination therapies

Publications (1)

Publication Number Publication Date
MX2022010171A true MX2022010171A (es) 2022-12-06

Family

ID=77391740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010171A MX2022010171A (es) 2020-02-19 2021-02-19 Inhibidores de setd2 y metodos y usos relacionados. que incluyen terapias de combinación.

Country Status (11)

Country Link
US (1) US20230133671A1 (https=)
EP (1) EP4107157A4 (https=)
JP (1) JP2023514280A (https=)
KR (1) KR20220143116A (https=)
CN (2) CN121695288A (https=)
AU (1) AU2021224855A1 (https=)
BR (1) BR112022016573A2 (https=)
CA (1) CA3168069A1 (https=)
IL (1) IL295654A (https=)
MX (1) MX2022010171A (https=)
WO (1) WO2021168313A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530844A (ja) 2017-08-14 2020-10-29 エピザイム,インコーポレイティド Setd2を阻害することにより癌を処置する方法
CN111093660A (zh) * 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
CN112585119A (zh) 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
US20240299352A1 (en) * 2021-06-09 2024-09-12 Epizyme, Inc. Combination therapies with setd2 inhibitors
JP2024539726A (ja) * 2021-11-01 2024-10-29 エピザイム,インコーポレイティド N-((1r,3s)-3-(4-アセチルピペラジン-1-イル)シクロヘキシル)-4-フルオロ-7-メチル-1h-インドール-2-カルボキサミドの結晶形態

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595766A (en) * 1984-10-26 1986-06-17 Ciba-Geigy Corporation Process for the preparation of an indoline carboxylic acid
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
NZ725860A (en) * 2014-04-04 2019-08-30 Iomet Pharma Ltd Indole derivatives for use in medicine
WO2016040505A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
CN112585119A (zh) * 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
SG11202105325QA (en) * 2018-11-30 2021-06-29 Epizyme Inc Methods of treating whsc1-overexpressing cancers by inhibiting setd2

Also Published As

Publication number Publication date
EP4107157A4 (en) 2024-03-13
BR112022016573A2 (pt) 2022-11-08
CA3168069A1 (en) 2021-08-26
WO2021168313A1 (en) 2021-08-26
KR20220143116A (ko) 2022-10-24
EP4107157A1 (en) 2022-12-28
CN115380033B (zh) 2026-01-09
AU2021224855A1 (en) 2022-09-08
CN121695288A (zh) 2026-03-20
CN115380033A (zh) 2022-11-22
US20230133671A1 (en) 2023-05-04
IL295654A (en) 2022-10-01
JP2023514280A (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
MX2022010171A (es) Inhibidores de setd2 y metodos y usos relacionados. que incluyen terapias de combinación.
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
CO2020001823A2 (es) Conjugados de citoquina para el tratamiento de enfermedades autoinmunes
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2018016227A (es) Terapias de combinacion.
CL2023003965A1 (es) Inhibidores cdk2.
MX2019004181A (es) Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano.
GT201700246A (es) Métodos y kits para tratar la depresión
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
UY37098A (es) Moduladores de ror-gamma
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
ECSP13012792A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CL2024002767A1 (es) Moduladores de nlrp3
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
CO2022014499A2 (es) Moduladores de nlrp3
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
CL2020002040A1 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos.
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
MX2021008941A (es) Moduladores gpr35.